CELGENE THALIDOMIDE APPROVAL WOULD GIVE PUBLIC A REGULATED SOURCE, CELGENE CEO ASSERTS; ADVISORY COMMITTEE RECOMMENDS FURTHER SAFETY DATA FROM PHASE IV
Executive Summary
FDA approval of thalidomide for erythema nodosum leprosum would benefit the public health by making available a version of the drug produced under good manufacturing practices and distributed under controlled conditions, Celgene CEO John Jackson declared during a teleconference Sept. 8.